Early Detection

Knowing what condition your patient is in at any given time is the key to improved patient care. 
BIOTRONIK Home Monitoring® early detects clinically relevant events and alerts physicians, allowing earlier intervention that increases the level of patient care.
 


When a clinically relevant status change occurs, BIOTRONIK Home Monitoring generates an event alert via email, SMS, or fax to the physician while simultaneously displaying the severity of the patients' status on the secure BIOTRONIK Home Monitoring website.

With just one click, physicians and nurses can quickly review the clinical status of patients at a glance, enabling them to provide the necessary assessment at the earliest stage possible.

The result is improved care, made simple and convenient.

The landmark trial TRUST1, the industry’s first finally published, large-scale, prospective, randomized study to demonstrate the benefits of Home Monitoring for ICD patients, has shown that 
BIOTRONIK Home Monitoring significantly reduces the time to evaluation of clinically relevant events such as arrhythmias1 and device-related issues2. Clinically relevant arrhythmia events were detected more than 34 days earlier in the Home Monitoring group as compared to the control group.


 

 

 

 


 

 

Based on the TRUST results, the regulatory authorities in the US and in Europe have extended approvals 
for BIOTRONIK Home Monitoring to include the early detection of clinically relevant events, including silent, asymptomatic arrhythmias*. This automatic early detection of arrhythmias and device system anomalies allows for earlier medical intervention than what is provided with conventional in-office follow-ups.

 

 

 1 Varma N, Epstein AE, Irimpen A, Schweikert R, Love C, for the TRUST investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: The Lumos-T safely reduces routine office device follow-up (TRUST) Trial. Circulation. 2010;122:325-332

2 Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: The Lumos-T safely reduces routine office device follow-up (TRUST) Trial. Circulation Arrhythmia and Electrophysiology. 2010;3:428-436

* BIOTRONIK Home Monitoring® is the first and only FDA and CE approved remote monitoring system to provide early detection of clinically relevant events.

 

 

Questions regarding this product?

Please fill out the contact form with your request for additional information, and you will receive an answer within 24 hours.

Contact Information:

* Mandatory fields

Patient Status Summary

Patient Notification Options 1

Patient Notification Options 2

Clinical information:

Varma N. et al.: Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The TRUST Trial. Circulation 2010;122:325-332

Abstract: click here

Varma N. et al.: Automatic Remote Monitoring of Implantable Cardioverter-Defibrillator Lead and Generator Performance: The TRUST Trial. Circulation Arrhythm Electrophysiol 2010;3;428-436

Abstract: click here

Full paper: click here